CLDX
Price
$26.40
Change
-$0.43 (-1.60%)
Updated
Dec 26 closing price
Capitalization
1.78B
65 days until earnings call
Intraday BUY SELL Signals
KRYS
Price
$252.28
Change
+$0.99 (+0.39%)
Updated
Dec 26, 04:59 PM (EDT)
Capitalization
7.29B
66 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CLDX vs KRYS

Header iconCLDX vs KRYS Comparison
Open Charts CLDX vs KRYSBanner chart's image
Celldex Therapeutics
Price$26.40
Change-$0.43 (-1.60%)
Volume$356.29K
Capitalization1.78B
Krystal Biotech
Price$252.28
Change+$0.99 (+0.39%)
Volume$3.67K
Capitalization7.29B
CLDX vs KRYS Comparison Chart in %
View a ticker or compare two or three
VS
CLDX vs. KRYS commentary
Dec 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLDX is a StrongBuy and KRYS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 27, 2025
Stock price -- (CLDX: $26.83 vs. KRYS: $251.29)
Brand notoriety: CLDX and KRYS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CLDX: 27% vs. KRYS: 38%
Market capitalization -- CLDX: $1.78B vs. KRYS: $7.29B
CLDX [@Biotechnology] is valued at $1.78B. KRYS’s [@Biotechnology] market capitalization is $7.29B. The market cap for tickers in the [@Biotechnology] industry ranges from $117.47B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CLDX’s FA Score shows that 0 FA rating(s) are green whileKRYS’s FA Score has 1 green FA rating(s).

  • CLDX’s FA Score: 0 green, 5 red.
  • KRYS’s FA Score: 1 green, 4 red.
According to our system of comparison, KRYS is a better buy in the long-term than CLDX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CLDX’s TA Score shows that 5 TA indicator(s) are bullish while KRYS’s TA Score has 3 bullish TA indicator(s).

  • CLDX’s TA Score: 5 bullish, 5 bearish.
  • KRYS’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, CLDX is a better buy in the short-term than KRYS.

Price Growth

CLDX (@Biotechnology) experienced а +4.11% price change this week, while KRYS (@Biotechnology) price change was +6.57% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.37%. For the same industry, the average monthly price growth was +0.28%, and the average quarterly price growth was +55.43%.

Reported Earning Dates

CLDX is expected to report earnings on Mar 02, 2026.

KRYS is expected to report earnings on Mar 02, 2026.

Industries' Descriptions

@Biotechnology (+0.37% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KRYS($7.29B) has a higher market cap than CLDX($1.78B). KRYS YTD gains are higher at: 60.405 vs. CLDX (6.173). KRYS has higher annual earnings (EBITDA): 165M vs. CLDX (-252.86M). KRYS has more cash in the bank: 731M vs. CLDX (583M). CLDX has less debt than KRYS: CLDX (2.62M) vs KRYS (9.51M). KRYS has higher revenues than CLDX: KRYS (373M) vs CLDX (2.6M).
CLDXKRYSCLDX / KRYS
Capitalization1.78B7.29B24%
EBITDA-252.86M165M-153%
Gain YTD6.17360.40510%
P/E RatioN/A37.67-
Revenue2.6M373M1%
Total Cash583M731M80%
Total Debt2.62M9.51M28%
FUNDAMENTALS RATINGS
CLDX vs KRYS: Fundamental Ratings
CLDX
KRYS
OUTLOOK RATING
1..100
7790
VALUATION
overvalued / fair valued / undervalued
1..100
68
Overvalued
80
Overvalued
PROFIT vs RISK RATING
1..100
9019
SMR RATING
1..100
9747
PRICE GROWTH RATING
1..100
4837
P/E GROWTH RATING
1..100
10096
SEASONALITY SCORE
1..100
3750

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CLDX's Valuation (68) in the Biotechnology industry is in the same range as KRYS (80) in the Pharmaceuticals Major industry. This means that CLDX’s stock grew similarly to KRYS’s over the last 12 months.

KRYS's Profit vs Risk Rating (19) in the Pharmaceuticals Major industry is significantly better than the same rating for CLDX (90) in the Biotechnology industry. This means that KRYS’s stock grew significantly faster than CLDX’s over the last 12 months.

KRYS's SMR Rating (47) in the Pharmaceuticals Major industry is somewhat better than the same rating for CLDX (97) in the Biotechnology industry. This means that KRYS’s stock grew somewhat faster than CLDX’s over the last 12 months.

KRYS's Price Growth Rating (37) in the Pharmaceuticals Major industry is in the same range as CLDX (48) in the Biotechnology industry. This means that KRYS’s stock grew similarly to CLDX’s over the last 12 months.

KRYS's P/E Growth Rating (96) in the Pharmaceuticals Major industry is in the same range as CLDX (100) in the Biotechnology industry. This means that KRYS’s stock grew similarly to CLDX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CLDXKRYS
RSI
ODDS (%)
Bearish Trend 3 days ago
69%
Bearish Trend 3 days ago
74%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
76%
Bearish Trend 3 days ago
84%
Momentum
ODDS (%)
Bearish Trend 3 days ago
78%
N/A
MACD
ODDS (%)
Bearish Trend 3 days ago
88%
Bullish Trend 3 days ago
75%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
80%
Advances
ODDS (%)
Bullish Trend 5 days ago
81%
Bullish Trend 4 days ago
80%
Declines
ODDS (%)
Bearish Trend 9 days ago
78%
Bearish Trend 9 days ago
74%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
74%
Bearish Trend 3 days ago
79%
Aroon
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 3 days ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
CLDX
Daily Signal:
Gain/Loss:
KRYS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HGHYX49.100.19
+0.39%
Hartford Healthcare Y
AMGAX18.320.07
+0.38%
Alger Mid Cap Growth A
ACEAX10.260.02
+0.20%
AB All China Equity A
OSCAX22.640.04
+0.18%
Invesco Main Street Small Cap A
JMGPX48.770.08
+0.16%
JPMorgan Mid Cap Growth R3

CLDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CLDX has been loosely correlated with BEAM. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if CLDX jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLDX
1D Price
Change %
CLDX100%
+0.94%
BEAM - CLDX
55%
Loosely correlated
+1.33%
XNCR - CLDX
55%
Loosely correlated
-0.13%
RVMD - CLDX
54%
Loosely correlated
+1.15%
KURA - CLDX
54%
Loosely correlated
+2.50%
VRDN - CLDX
54%
Loosely correlated
+0.53%
More

KRYS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KRYS has been loosely correlated with XNCR. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if KRYS jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KRYS
1D Price
Change %
KRYS100%
-0.82%
XNCR - KRYS
46%
Loosely correlated
-0.13%
VRDN - KRYS
46%
Loosely correlated
+0.53%
CGON - KRYS
46%
Loosely correlated
+0.22%
IDYA - KRYS
45%
Loosely correlated
+0.76%
ZLDPF - KRYS
45%
Loosely correlated
N/A
More